Mecamylamine Effects on Haloperidol-Induced Catalepsy and Defecation

References

• Balfour D. J., Benwell M. E., Birrell C. E., Kelly R. J., Al-Aloul M. Sensitization of the mesoaccumbens dopamine response to nicotine. Pharmacology Biochemistry Behavior 1998; 59: 1021–30
   PubMed Web of Science ®Google Scholar
• Benowitz N. L. Nicotine addiction [In Process Citation]. Prim Care 1999; 26: 611–31
   PubMed Web of Science ®Google Scholar
• Corrigall W. A., Franklin K. B., Coen K. M., Clarke P. B. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 1992; 107: 285–9
   PubMed Web of Science ®Google Scholar
• Dani J. A., Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron 1996; 16: 905–8
   PubMed Web of Science ®Google Scholar
• Driscoll P. Nicotine-like behavioral effect after small dose of mecamylamine in Roman high-avoidance rats. Psychopharmacologia 1976a; 46: 119–21
   PubMed Web of Science ®Google Scholar
• Driscoll P. Nicotine-like behavioral effect after small dose of mecamylamine in roman high-avoidance rats. Psychopharmacologia 1976b; 46: 119–121
   PubMed Web of Science ®Google Scholar
• Driscoll P., Battig K. Cigarette smoke and behavior: some recent developments. Reviews of Environmental Health 1973a; 1: 113–133
   Google Scholar
• Driscoll P., Battig K. The effect of small doses of mecamylamine on shuttlebox behavior in the guinea-pig. Experientia 1973b; 29: 991–3
   PubMedGoogle Scholar
• Emerich D., Sanberg P., Manderscheid P., McConville B., Rich J., El-Etri M., Shipley M., Norman A. Differential effect of nicotine on D1 v.5. D2 antagonist-induced catalepsy. Society for Neuroscience Abstracts 1990; 16: 247
   Google Scholar
• Emerich D. F., Norman A. B., Sanberg P. R. Nicotine potentiates the behavioral effects of haloperidol. Psychopharmacology Bulletin 1991a; 27: 385–90
   PubMedGoogle Scholar
• Emerich D. F., Zanol M. D., Norman A. B., McConville B. J., Sanberg P. R. Nicotine potentiates halopendol-induced catalepsy and locomotor hypo-activity. Pharmacology Biochemistry and Behavior 1991b; 38: 875–80
   PubMed Web of Science ®Google Scholar
• Hulihan-Giblin B. A., Lumpkin M. D., Kellar K. J. Acute effects of nicotine on prolactin release in the rat: Agonist and antagonist effects of a single injection of nicotine. The Journal of Pharmacology and Experimental Therapeutics 1990; 252: 15–20
   PubMed Web of Science ®Google Scholar
• Levin E. D., Lippiello P. Mutually Potentiating Effects of Mecamylamine and Haloperidol in Producing Catalepsy in Rats. Drug Development Research 1999; 47: 90–96
   Web of Science ®Google Scholar
• Lukas R. J., Ke L., Bencherif M., Eisenhour C. M. Regulation by nicotine of its own receptors. Drug Development Research 1996; 38: 136–148
   Web of Science ®Google Scholar
• Moss D. E., Manderscheid P. Z., Kobayashi H., Montgomery S. P. Evidence for the nicotinic cholinergic hypothesis of cannabinoid action within the central nervous system: Extrapyramidal motor behaviors. Marijuana: An international Research Report, G. Chesher, P. Consroe, R. Musty. Australian Government Printing Service, Canaberra, Australia 1988; 359–364
   Google Scholar
• Newman M. B., Nazian S., Sanberg P. R., Diamond D., Shytle R. D. Corticosterone-Attenutating and Anxiolytic Properties of Mecamylamine in the Rat. Progress in NeuroPsychopharmacological & Biological Psychiatry 2000; 25(3)609–620
   Web of Science ®Google Scholar
• Perkins K. A. Baseline-dependency of nicotine effects: a review (see comments). Behavioural Pharmacology 1999; 10: 597–615
   PubMed Web of Science ®Google Scholar
• Pidoplichko V. I., DeBiasi M., Williams J. T., Dani J. A. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 1997; 390: 401–4
   PubMed Web of Science ®Google Scholar
• Rose J. E., Behm F. M., Westman E. C. Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Experimental and Clinical Psychopharmacology 1998; 6: 331–43
   PubMed Web of Science ®Google Scholar
• Rose J. E., Behm F. M., Westman E. C., Levin E. D., Stein R. M., Ripka G. V. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clinical Pharmacology and Therapeutics 1994; 56: 86–99
   PubMed Web of Science ®Google Scholar
• Sanberg P., Martinez R., Shytle R., Cahill D. The Catalepsy Test: Is a Standardized Method Possible?. Motor activity and movement disorders: Research issues and applications, P. Sanberg, K. Ossenkopp, M. Kavaliers. Humana Press, New Jersey 1995; 197–211
   Google Scholar
• Sanberg P. R. Neuroleptic-induced emotional defecation: effects of pimozide and apomorphine. Physiological Behaviour 1989; 46: 199–202
   PubMed Web of Science ®Google Scholar
• Sanberg P. R., Emerich D. F., el-Etri M. M., Shipley M. T., Zanol M. D., Cahill D. W., Norman A. B. Nicotine potentiation of haloperidol-induced catalepsy: striatal mechanisms. Pharmacology Biochemistry and Behavior 1993; 46: 303–7
   PubMed Web of Science ®Google Scholar
• Sanberg P. R., McConville B. J., Fogelson H. M., Manderscheid P. Z., Parker K. W., Blythe M. M., Klykylo W. M., Norman A. B. Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome. Biomed. Pharmacother. 1989; 43: 19–23
   PubMed Web of Science ®Google Scholar
• Sanberg P. R., Silver A. A., Shytle R. D. Treatment of Tourette's Syndrome with Nicotinic antagonist mecamylamine American College of Neuropsychophar-macology. 36th Annual Meeting, Waikoloa, Hawaii, 1997a; 249
   Google Scholar
• Sanberg P. R., Silver A. A., Shytle R. D. Treatment of Tourette's Syndrome with Mecamylamine. Lancet 1998; 352: 705–706
   PubMed Web of Science ®Google Scholar
• Sanberg P. R., Silver A. A., Shytle R. D., Philipp M. K., Cahill D. W., Fogelson H. M., McConville B. J. Nicotine for the treatment of Tourette's syndrome. Pharmacology and Therapeutics 1997b; 74: 21–5
   PubMed Web of Science ®Google Scholar
• Shytle R. D., Silver A. A., Philipp M. K., McConville B. J., Sanberg P. R. Transdermal Nicotine for Tourette's Syndrome. Drug Development Research 1996; 38: 290–298
   Web of Science ®Google Scholar
• Shytle R. D., Silver A. A., Wilkinson B. J., Newman M. B., Katherine-Phihp M., Sanberg P. R., McConville B., Fogelson H. Treatment of Tourette Disorder with Transdermal Nicotine and Haloperidol IBC's. Advances in Molecular Pharmacology and Drug Development. 1999, 2nd International Symposium on Nicotinic Acetylcholine Receptors,Annapolis, MD
   Google Scholar
• Silver A. A., Shytle R. D., Philipp M. K., Sanberg P. R. Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome. Journal American Academy of Child Adolescent Psychiatry 1996; 35: 1631–6
   PubMed Web of Science ®Google Scholar
• Silver A. A., Shytle R. D., Sanberg P. R. Clinical Experience with Mecamylamine in Tourette Syndrome. Journal of Child and Adolescent Psycho-pharmacology 2000; 10: 59–68
   PubMed Web of Science ®Google Scholar
• Stone C. A., Mecklenburg K. L., Torchiana M. L. Antagonism of nicotine-induced convulsions by ganglionic blocking drugs. Pharmacology and Experimental Therapeutics. 1956; 15
   Google Scholar
• Terry A. V., Buccafusco J. J., Prendergast M. A. Dose-specific improvements in memory-related performance by rats and aged monkeys administered the nicotinic-cholinergic antagonist mecamylamine. Drug Development Research 1999; 47: 127–136
   Web of Science ®Google Scholar
• Tizabi Y., Copeland R. L., Jr, Brus R., Kostrzewa R. M. Nicotine blocks quinpirole-induced behavior in rats: psychiatric implications. Psychophurmacology (Berl) 1999; 145: 433–41
   PubMed Web of Science ®Google Scholar
• Tizabi Y., Mastropaolo J., Park C. H., Riggs R. L., Powell D., Rosse R. B., Deutsch S. I. Both nicotine and mecamylamine block dizocilpine-induced explosive jumping behavior in mice: psychiatric implications. Psychopharmacology (Berl) 1998; 140: 202–5
   PubMed Web of Science ®Google Scholar
• Ushijima I., Mizuki Y., Imaizumi J., Yamada M., Noda Y., Yamada K., Furukawa T. Characteristics of yawning behavior induced by apomorphine, physostigmine and pilocarpine. Archives International Pharmacodyname Therapy 1985; 273: 196–201
   PubMedGoogle Scholar
• Zarrindast M. R., Shekarchi M., Rezayat M. Effect of nicotine on apomorphine-induced licking behaviour in rats (In Process Citation). European Neurorpsychopharmacoi 1999; 9: 235–8
   PubMed Web of Science ®Google Scholar